Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells Publisher Pubmed



Dianatmoghadam H^{1, 2, 3} ; Rokni M⁴ ; Marofi F⁵ ; Panahi Y⁶ ; Yousefi M^{2, 3, 7} Show Affiliations
Source: Journal of Cellular Physiology Published:2018

Abstract

Natural killer (NK) cells are key players of the innate immune system. NK cells provide protection against infectious pathogens and malignancies in cell. This characteristic may be attributable to their intrinsic diverse potentialities and also their cooperation with adaptive immune lymphocytes, known as B and T cells. The growth, recurrence, and metastasis of cancer cells, and the failure of cytoreductive therapies against cancer cells are due to the small population of intratumor stem-like cells, called cancer stem cells (CSCs). Furthermore, NK cells can efficiently eradicate heterogeneous tumor cells after a long-term treatment. Therefore, NK cell–based therapy is a promising strategy to target and break CSC-associated resistance to anticancer drugs treatment. In this review, we have presented an overview of the emerging knowledge of the characteristics, diversities, and mechanism-driven immune surveillance of human NK cells and advances in NK cell–based immunotherapies. Finally, we will discuss how these cells can be applied to introduce the next generation of vaccine- and immune-based approaches to prevent drug resistance. © 2018 Wiley Periodicals, Inc.